We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

60 hedge funds and large institutions have $15.3M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

319% more call options, than puts

Call options by funds: $381K | Put options by funds: $91K

2% less capital invested

Capital invested by funds: $15.6M → $15.3M (-$263K)

5% less funds holding

Funds holding: 63 → 60 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
13
Closed
11
Calls
$381K
Puts
$91K
Net Calls
+$290K
Net Calls Change
-$17K

Top Buyers

Rank Fund Capital Flow
1
WE
Wealth Effects
Massachusetts
+$729K
2
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
+$161K
3
GJL
Gendell Jeffrey L
+$123K
4
IAIM
International Assets Investment Management
Florida
+$52.7K
5
TCOT
Trust Company of Toledo
Ohio
+$41K

Top Sellers

Rank Fund Capital Flow
1
Group One Trading
Group One Trading
Illinois
-$735K
2
OMC
Oasis Management Company
Cayman Islands
-$577K
3
BlackRock
BlackRock
New York
-$93.7K
4
Millennium Management
Millennium Management
New York
-$93.7K
5
GCP
GSA Capital Partners
United Kingdom
-$71K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$7.2K -$5.86K -2 -40%
SS
52
Simplicity Solutions
Minnesota
$6.91K +$8.78K +3 New
NFSG
53
Newbridge Financial Services Group
Florida
$5.53K – – –
IA
54
IFP Advisors
Florida
$4.58K – – –
Bank of America
55
Bank of America
North Carolina
$2.71K – – –
FIA
56
FNY Investment Advisers
New York
$2K – – –
HCM
57
Hollencrest Capital Management
California
$1.8K – – –
UBS Group
58
UBS Group
Switzerland
$1.54K -$5.86K -2 -67%
TWC
59
TD Waterhouse Canada
Ontario, Canada
$1.47K – – –
Fidelity Investments
60
Fidelity Investments
Massachusetts
$1.43K – – –
VWM
61
Venturi Wealth Management
Texas
$1.11K – – –
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$1K -$2.93K -1 Closed
BC
63
Bartlett & Co
Ohio
$1K – – –
TRCT
64
Tower Research Capital (TRC)
New York
$1K – – –
National Bank of Canada
65
National Bank of Canada
Quebec, Canada
$693 – – –
BCWM
66
Bartlett & Co Wealth Management
Ohio
$691 – – –
WIM
67
Westside Investment Management
California
$691 – – –
PA
68
Parallel Advisors
California
$587 – – –
FCA
69
FinTrust Capital Advisors
South Carolina
$340 – – –
AAS
70
Ameritas Advisory Services
Nebraska
$326 – – –
PNC Financial Services Group
71
PNC Financial Services Group
Pennsylvania
$218 – – –
TWA
72
TCI Wealth Advisors
Arizona
$139 – – –
US Bancorp
73
US Bancorp
Minnesota
$69 – – –
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$49 – – –
Commonwealth Equity Services
75
Commonwealth Equity Services
Massachusetts
$20 – – –
1 2
3
4

SEEL Hedge Fund Activity: Q1 2023 in Review

60 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q1 2023, worth a combined $15.3M — down 1.7% from $15.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of SEEL and 8 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was Wealth Effects, opening a new position worth an estimated $729K. The largest seller was Group One Trading, cutting an estimated $735K.

  • 60 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q1 2023, down from 63 in Q4 2022.
  • Funds reported $15.3M of Seelos Therapeutics, Inc. Common Stock stock for Q1 2023, down 1.7% quarter-over-quarter.
  • 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q1 2023 and 11 closed out, a net change of -3 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q1 2023 was Wealth Effects, an estimated $729K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q1 2023 was Group One Trading, an estimated $735K sold.

Based on aggregated 13F filings for Q1 2023.